Mutations affecting epigenetic regulators—including DNMT3A, TET2, IDH1/2, ASXL1, and KMT2A rearrangements—are not uncommon in MS and further support the contribution of epigenetic mechanisms to its pathogenesis [7,15,58]. This evidence concerns the gene ASXL1 and myeloid sarcoma.